Zenas BioPharma's Clinical Pipeline Faces Scrutiny Amid Rising Cash Burn
Zenas BioPharma (NASDAQ: ZBIO) is at a pivotal stage, with its lead drug candidate obexelimab nearing potential FDA approval for IgG4-related disease. The company reported that the FDA accepted its Biologics License Application in August, setting an action date of May 27, 2027. Strong Phase 3 trial results showed significant efficacy compared to placebo, and international expansion efforts are underway with Bristol Myers Squibb submitting a marketing application for Japan. Despite these regulatory advances, Zenas continues to face financial challenges. The company's second-quarter net loss surged to $111.5 million from $52.2 million in the same period last year due to rising R&D and administrative costs. Additional expenses include milestone payments under licensing agreements with Xencor and InnoCare, as well as increased interest obligations. The firm is also preparing for a potential commercial launch by adding experienced leadership and developing more convenient delivery methods for obexelimab.
